Biocon is a global biopharmaceutical company transforming access to healthcare through affordable innovation. Guided by our shared mission, we are focused on delivering lifesaving therapies to …

Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of MAbs and cancer vaccines.

Biocon Biologics is transforming patient outcomes by making life-changing therapies more accessible to the world. Through affordable biosimilars, we are reducing the global healthcare burden, increasing …

Biocon Biologics has emerged as a leader in biosimilars in the U.S. and worldwide, providing innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases.

Biocon is aiming to support its generics business while complementing the momentum of its biosimilars segment.

Dec 6, 2025 · Biocon, which had earlier been pushing its IPO plans, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt.

Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company.

May 8, 2026 · Shares of Biocon are trading higher in trade on Friday after the company reported its fourth quarter earnings in the financial year ending March 2026. The stock is currently trading at Rs …

May 5, 2026 · As part of a wider organisational overhaul, Biocon has merged its generics and biologics businesses, reduced debt, and simplified its structure. The company is focusing on biosimilars, which …

Dec 8, 2025 · She founded Biocon in 1978 and turned it into a biopharmaceutical giant. The company acquired U.S. drugmaker Viatris’ biosimilars business for $3.3 billion in 2022.